Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445566 | 1.00 | TDP1 (0.31) | TDP1LMNAALOX15BLMPMP22 | |
| SCHEMBL30808136 | 1.00 | TDP1 (0.31) | TDP1LMNAALOX15BLMPMP22 | |
| Sulfuric Acid SCHEMBL3395417 | 0.92 | — | — | |
| Lactic Acid SCHEMBL339840 | 0.92 | TP53 (0.42) | — | |
| Acrylamide SCHEMBL21723571 | 0.90 | ALDH1A1 (0.41) | TDP1ALDH1A1 | |
| Methacrylic Acid SCHEMBL4418618 | 0.89 | TDP1 (0.38) | TDP1 | |
| SCHEMBL31482770 | 0.85 | — | — | |
| SCHEMBL3232685 | 0.84 | GRIK1 (0.41) | TDP1LMNAALOX15BLMPMP22 | |
| SCHEMBL630861 | 0.84 | GRIK1 (0.41) | TDP1LMNAALOX15BLMPMP22 | |
| SCHEMBL2047661 | 0.84 | TDP1 (0.32) | TDP1LMNAALOX15BLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 587 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025260203-A1 | CLICK CHEMISTRY POLYMER HYDROGELS | ALLARTA LIFE SCIENCE INC. (CA) | 2025-12-26 | — | — | WO | claimed |
| WO-2025260204-A1 | CROSSLINKED HYDROGELS WITH CONTROLLED PERMEABILITY | ALLARTA LIFE SCIENCE INC. (CA) | 2025-12-26 | — | — | WO | claimed |
| EP-4658249-A1 | COMPOSITIONS AND METHODS | BioNTech SE (DE) | 2025-12-10 | — | — | EP | claimed |
| EP-4658248-A1 | COMPOSITIONS AND METHODS | BioNTech SE (DE) | 2025-12-10 | — | — | EP | claimed |
| EP-4658250-A1 | COMPOSITIONS AND METHODS | BioNTech SE (DE) | 2025-12-10 | — | — | EP | claimed |
| EP-4452643-B1 | PROCESS FOR MANUFACTURING A MICROFLUIDIC DEVICE | SURFIX B V (NL) | 2025-11-26 | — | — | EP | claimed |
| WO-2025222234-A1 | TARGETED DENDRIMER CONJUGATES | STARPHARMA PTY LTD (AU) | 2025-10-30 | — | — | WO | claimed |
| US-12358271-B2 | Process for manufacturing a microfluidic device | SURFIX B.V. (NL) | 2025-07-15 | — | — | US | claimed |
| EP-4572732-A1 | COMPOSITIONS AND RELATED METHODS | Colgate-Palmolive Company (US) | 2025-06-25 | — | — | EP | claimed |
| WO-2025093665-A1 | PARTICLES, COMPOSITIONS AND METHODS | BioNTech SE (DE) | 2025-05-08 | — | — | WO | claimed |
| US-20110059040-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL AND BACTERIAL ACTIVITY | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-03-10 | — | — | US | claimed |
| EP-2173362-A2 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL AND BACTERIAL ACTIVITY | University Of Utah (US) | 2010-04-14 | — | — | EP | claimed |
| WO-2009003090-A2 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL AND BACTERIAL ACTIVITY | UNIVERSITY OF UTAH (US) | 2008-12-31 | — | — | WO | claimed |
| EP-1027379-B1 | METHOD FOR PRODUCING POLYMERIC SOLID PHASE SUPPORTING MATERIALS | POLY AN GES ZUR HERSTELLUNG VO (DE) | 2007-02-28 | — | — | EP | claimed |
| EP-1510533-B1 | Block copolymer comprising a vinylactam block, cosmetic composition and use of this polymer in cosmetics | OREAL (FR) | 2006-12-06 | — | — | EP | claimed |
| US-7041164-B2 | Dental etch solutions | Kanca, III, John A. (US) | 2006-05-09 | — | — | US | claimed |
| EP-0700295-A4 | VITAMIN B 12? MEDIATED ORAL DELIVERY SYSTEMS FOR GCSF AND EPO | BIOTECH AUSTRALIA PTY LTD (AU) | 1998-09-30 | — | — | EP | claimed |
| CN-1126441-A | Amplification of vitamin B12 absorption System Using polymers | BIOTECH AUSTRALIA PTY LTD (AU) | 1996-07-10 | — | — | CN | claimed |
| EP-0700295-A1 | VITAMIN B 12? MEDIATED ORAL DELIVERY SYSTEMS FOR GCSF AND EPO | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1996-03-13 | — | — | EP | claimed |
| WO-1994027613-A1 | VITAMIN B12 MEDIATED ORAL DELIVERY SYSTEMS FOR GCSF AND EPO | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1994-12-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059040-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL AND BACTERIAL ACTIVITY | BLVRB, RNASE1, BPGM | TDP1 1385/4885LMNA 1943/4885ALOX15 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.